AstraZeneca to seek approval for blood pressure drug by year-end

AstraZeneca (AZN.L) plans to file for regulatory approval of its experimental blood pressure drug, baxdrostat, by year-end, targeting 2026 approvals in the U.S. and EU. This novel aldosterone-targeting treatment is seen as key to AZN's long-term sales strategy, with peak annual sales projected to exceed $5 billion, supported by advanced trial data showing a 9.8 mmHg reduction in systolic blood pressure for hard-to-control hypertension. The move positions AstraZeneca against rival Mineralys Therapeutics, which also plans a year-end FDA submission for its similar drug, signaling a competitive and growing market for advanced hypertension treatments, despite both drugs showing a common side effect of hyperkalaemia.

Analysis

AstraZeneca is advancing its experimental hypertension drug, baxdrostat, with plans to file for regulatory approval by year-end, targeting a 2026 launch. This move is central to the company's long-term growth, underscored by a management forecast of over $5 billion in peak annual sales. The drug's novel mechanism, which targets the hormone aldosterone, addresses a significant unmet need in a market of over 1 billion people with high blood pressure. Advanced trial data showed a placebo-adjusted 9.8 mmHg reduction in systolic blood pressure at the 2mg dose, which is robust but falls just short of the 10-12 mmHg reduction some physicians polled by TD Cowen were hoping for. The competitive landscape is clearly defined, with Mineralys Therapeutics' rival drug, lorundrostat, showing a comparable 9.1 mmHg reduction and also targeting a year-end FDA submission. This sets up a direct race to market. A key safety consideration is the 1.1% incidence of hyperkalaemia, a side effect also observed with lorundrostat, suggesting it may be a class-wide effect rather than a specific disadvantage for baxdrostat.

Key Decisions for Investors

• Investors should view this development as a significant de-risking event for a key asset in AstraZeneca's late-stage pipeline, supporting the company's long-term revenue outlook beyond 2026.
• The near-identical efficacy and safety profiles between baxdrostat and Mineralys' lorundrostat mean that first-to-market status and commercial execution will be critical; monitor regulatory submission and review timelines for both companies closely.
• While the $5 billion peak sales target is compelling, investors should consider that the 9.8 mmHg efficacy result, while strong, may not be a definitive best-in-class figure, potentially leading to a highly competitive market dynamic rather than outright dominance.
• Given the shared hyperkalaemia side effect, any differentiation in the final safety labeling or post-market surveillance data for either drug could meaningfully impact physician adoption and market share.